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The human cytomegalovirus (HCMV) homolog of the Epstein-Barr virus (EBV) protein kinase (PK),
UL97, is inhibited by maribavir (1263W94) and selected indolocarbazoles. Here we show that only one of
these indolocarbazoles (K252a), but not maribavir, inhibits autophosphorylation of the EBV PK, BGLF4.
However, maribavir and another indolocarbazole, NGIC-I, do inhibit EBV DNA synthesis, suggesting
that although these last compounds inhibit both HCMV and EBV, they seem to operate through differ-
ent pathways.
The family Herpesviridae contains approximately 130 herpes-
viruses from different animal species (28). Despite remarkable
differences in biological properties among the members of the
family, their genomes encode many conserved genes (28). This
conservation may suggest important roles for the products of
these genes in the viral life cycle. All known herpesvirus ge-
nomes contain genes that encode known or putative protein
kinases (PKs) (4, 30), the functions of which are largely unde-
termined. The members of this family can be divided into two
main groups; each group is exemplified by the most-studied
members encoded by herpes simplex virus US3 (9, 19, 27) and
UL13 (7, 23) genes. While alphaherpesviruses encode mem-
bers of both PK groups, beta- and gammaherpesviruses encode
only one PK, which is the homolog of herpes simplex virus
UL13, a PK involved in modification of a number of viral (20,
21, 25, 26) and cellular (3, 14) proteins. Recent reports have
linked the anti-human cytomegalovirus (HCMV) effects of
the novel antiviral compound maribavir (6) to the inhibition of
the virally encoded PK UL97 (2, 11, 33). The results suggest
that both the inhibition of UL97 kinase activity and the dele-
tion of the UL97 gene lead to a significant decrease in viral
yield (16, 24), presumably due to inhibition of the nuclear
egress of virions (16). The results also support previous data
that suggest an important role for this kinase in the viral life
cycle (32).
Epstein-Barr virus (EBV) PK encoded by the BGLF4
gene is a homolog of HCMV UL97. Previously, members of
our group (34) and others (31) have reported that EBV is
the only other human herpesvirus inhibited by maribavir; we
have also shown that the hyperphosphorylation of EBV
EA-D (encoded by the EBV BMRF1 gene), the viral DNA
polymerase processivity factor, is correlated with PK ex-
pression, therefore implying a role for EBV PK in viral rep-
lication and a possible mechanism of action for the drug.
However, although maribavir inhibited the level of hyper-
phosphorylated EA-D during viral reactivation in Akata cells,
it did not directly inhibit the phosphorylation of EA-D by EBV
PK in transient coexpression assays with these two viral genes
(10).
In the continuous search for more potent and selective an-
tiviral compounds, unmodified indolocarbazole Arcyriaflavin
A was proposed as a potent inhibitor of HCMV in vitro (29).
Additional screening revealed a number of indolocarbazoles
showing pronounced anti-HCMV effects (29, 35), presumably
due to the specific targeting of HCMV UL97 (17, 18, 35). In
the present study we tested the anti-EBV activity of maribavir
and selected indolocarbazoles (K252a, K252c, Gö6976, and
NGIC-I) (Fig. 1) in vivo as well as their effect on purified EBV
PK in vitro.
The EBV BGLF4 gene (genomic position, 110040 to 111404
[complement]; NCBI accession number AJ507799) or the gene
encoding the K102I mutant of BGLF4, in which the invariant
catalytic lysine was mutated, was cloned into a baculovirus
genome as a fusion with sequence for glutathione S-transferase
and His6 tags (12, 13) (the viruses were a gift from Y. Kawagu-
chi) and was expressed in insect cells by following standard
protocols (22). The protein purification and in vitro kinase
assay protocols were described previously (12). The purifica-
tion efficiency in this study was routinely around 95% (by
Coomassie staining) (Fig. 2A).
First, we tested the kinase activity of the purified kinase or
its catalytic knockout on nonspecific exogenous substrates and
in autophosphorylation assays as well (Fig. 2B and C). Equal
amounts (2 g) of casein, histone 2B, myelin basic protein
(MBP), and protamine were incubated in the kinase assays in
the presence or absence of the kinase for 30 min at 37°C. The
whole reaction mixtures were separated on sodium dodecyl
sulfate (SDS)-polyacrylamide gels (4 to 20% gels), transferred
onto a polyvinylidene difluoride membrane, and after staining
with Ponceau S (Sigma), exposed to a film (Kodak) for auto-
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radiography. The results show that EBV PK was highly effi-
cient in phosphorylation of MBP and in autophosphorylation,
which supports previous observations of basic substrate pref-
erence (histone versus casein) (5). Histone 2B was phosphor-
ylated to a lesser extent (Fig. 2B). No phosphorylation was
detected in the presence of the BGLF4 K102I mutant (Fig.
2C) and in the absence of the kinase (data not shown). Auto-
phosphorylation was selected as a measure of the kinase activ-
ity.
Second, we examined the effect of anti-HCMV UL97 com-
pounds on EBV PK autophosphorylation. The compounds
from an indolocarbazole group (K252a, K252c, Gö6976, and
NGIC-I) were selected based on their effectiveness against
HCMV UL97 (18, 35) and purchased from Calbiochem;
maribavir was provided by GlaxoSmithKline (RTP). Con-
centrations ranged between 0.0001 and 1 M, and the re-
sults presented are from the highest concentration. As shown
in Fig. 3, only one of four compounds could effectively
inhibit autophosphorylation of EBV PK. This compound,
K252a, has a much broader range of targets (such as PKA,
PKC, PKG, calmodulin kinase, myosin light-chain kinase,
and tyrosine kinase) than the other compounds tested (which
are mainly PKC inhibitors). These results support recent
data, which showed that NGIC-I did not inhibit the phos-
phorylation of ganciclovir by EBV PK while it did inhibit
phosphorylation of ganciclovir by HCMV UL97 (17, 18).
Finally, these results are congruent with the failure of mariba-
vir to inhibit phosphorylation of EA-D by EBV PK in trans-
fected cells (10)
Last, we examined the cytotoxicities of these compounds
on latently infected Akata cells by a modified MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay
(Promega) and their effects on EBV lytic replication by mea-
suring EBV DNA levels. For the cytotoxicity assay, the cells
were seeded at low density in 96-well plates (in triplicate) and
treated with different concentrations (0.001 to 100 M) of the
selected compounds. Assay buffer was added 5 days after treat-
ment, and measurements were performed according to the
manufacturer’s protocol. The results (Table 1) show that all
tested indolocarbazoles are toxic to the cells at concentrations
of 3 M or less, with K252c being the least toxic (concen-
tration resulting in 50% inhibition of cellular activity [CC50],
3.14 M) and K252a being the most toxic (CC50, 0.18 M).
On the other hand, maribavir’s toxicity was insignificant
(less than 20% at 10 M) at the concentration tested (CC50,
93 M).
For the antiviral activity tests, cytolytic EBV replication was
induced in latently infected Akata cells as described previously
(10); simultaneously, the cells were treated with the com-
pounds as described above, and total DNA was isolated 48 h
after viral reactivation. Equal amounts of the total lysates were
dot blotted onto nitrocellulose membranes and hybridized with
32P-labeled BGLF4 or BaRF1 genes used as probes. The
hybridization efficiency was quantitated on a phosphorim-
ager. Detected viral DNA represents largely newly synthe-
sized DNA, since basal EBV DNA in the latently infected
Akata cells is about 20 viral genomes (episomes) per cell (8).
The results showed the following: (i) K252a, K252c, and
Gö6976 were effective only at cytotoxic concentrations (ther-
apeutic indices are 9, 3, and 4, respectively); (ii) maribavir
and NGIC-I, on the other hand, effectively inhibited EBV
DNA synthesis at levels significantly below cytotoxic concen-
trations (therapeutic indices are 148 and 153, respectively)
(Table 1).
Several recent studies propose HCMV UL97 as an attractive
target for antiviral therapy based on its importance in the viral
life cycle (32) and the specific inhibition of UL97 kinase activ-
ity by several compounds with potential antiviral effects (1, 17,
18, 35). In the present study we examined the ability of selected
FIG. 1. Chemical structures of potential antiviral compounds and maribavir.
TABLE 1. Antiviral activities of maribavir and selected
indolocarbazoles against EBV and cytotoxicity
in Akata cellsa
Compound CC50 (M) IC50 (M)
Therapeutic
index
Maribavir 93  1 0.63  0.02 148
K252a 0.18  0.03 0.02  0.001 9
K252c 3.14  0.07 1.11  0.03 3
Gö6976 0.41  0.021 0.11  0.02 4
NGIC-I 0.61  0.02 0.004 153
a Values are expressed as means  standard deviations of three replicate
assays. The assay value of 0.004 M is assigned a value of 0.004 M for the
purpose of the calculation, and the mean value is designated by the symbol “.”
CC50, concentration of the compound that resulted in 50% inhibition of cellular
activity in MTT assays; IC50, concentration of the compound that resulted in
50% reduction of viral DNA level; therapeutic index, CC50/IC50.
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compounds to inhibit the kinase activity of the UL97 homolog,
EBV PK, encoded by the BGLF4 gene, in vitro and the ability
of these compounds to inhibit EBV DNA synthesis in vivo.
This study demonstrated that three of four indolocarbazoles
that we tested (K252a, K252c, and Gö6976) were toxic for the
Akata cells, and their “antiviral” effect in our system is merely
the result of cytotoxicity (Table 1). However, the therapeutic
index for NGIC-I, which also showed relatively high cytotox-
icity, is 153, which makes this compound at least as efficient
as maribavir in EBV inhibition (Table 1), and thus, it may
warrant additional studies for its potential usefulness. In addi-
tion, the results show that the inhibitor of HCMV and EBV
replication, maribavir, with a known inhibitory effect on
HCMV UL97 kinase activity (1), has virtually no such effect on
the activity of EBV PK (10) (Fig. 3); on the other hand, K252a,
which inhibited both kinases (35) (Fig. 3) and HCMV replica-
tion (35), has an insignificant effect on EBV replication at
noncytotoxic levels (Table 1). Therefore, our data imply that
inhibition by maribavir of HCMV and EBV replication op-
erates through different pathways. The recent discovery of
maribavir-resistant HCMV bearing a mutation in the UL27
gene, which has no homolog in EBV, and no mutations in
the UL97 gene (15) supports this statement. Thus, this and
our previous studies (10) as well as reports from other
groups clearly show that despite the homology between
HCMV UL97 and EBV PK, these proteins might play dis-
tinct roles in the viral lytic cycle, and these roles are yet to
be identified.FIG. 2. Purification and kinase activity of EBV PK. (A) EBV PK was
expressed in insect cells infected with recombinant baculovirus and puri-
fied following a published protocol (12). The purified protein appears as a
single band at 78 kDa detected by Coomassie staining. Numbers on
the right side of the gel are standard molecular weights in thousands.
(B) Kinase activity of the purified EBV PK was examined in in vitro
kinase assays with casein, MBP, histone 2B, and protamine as sub-
strates (lower panel) or in autophosphorylation assays (upper pa-
nel). The whole reaction mixtures were separated by SDS-PAGE
(4 to 20% gradient gel), and dried gels were exposed to X-ray film. No
labeled bands were detected in mock reactions (without kinase) (data
FIG. 3. Inhibition of EBV PK kinase activity by selected com-
pounds. A 1 M concentration of each compound was added to the
kinase assay samples. The control sample was treated with an equal
amount of dimethyl sulfoxide. The reaction mixtures were separated by
SDS-PAGE, transferred to a polyvinylidene difluoride membrane, and
exposed to X-ray film (upper panel) followed by probing with anti-
glutathione S-transferase antibody (bottom panel).
not shown). (C) Specificity of the autophosphorylation was confirmed
by use of the kinase-null K102I mutant of EBV BGLF4. The kinase
assays were performed as described before, and the reaction mixtures
were extensively washed, subjected to SDS-PAGE, and exposed to
X-ray film (upper panel), followed by immunoblotting with anti-GST
antibody (bottom panel).
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